Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
In this clinical trial, the appetite suppressant sibutramine as compared with placebo resulted in modest weight loss but also in an unexpected increase in the risk of nonfatal myocardial infarction and stroke (a finding limited to patients with preexisting cardiovascular disease). Sibutramine should...
Saved in:
| Published in | The New England journal of medicine Vol. 363; no. 10; pp. 905 - 917 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article Web Resource |
| Language | English |
| Published |
Waltham, MA
Massachusetts Medical Society
02.09.2010
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | In this clinical trial, the appetite suppressant sibutramine as compared with placebo resulted in modest weight loss but also in an unexpected increase in the risk of nonfatal myocardial infarction and stroke (a finding limited to patients with preexisting cardiovascular disease). Sibutramine should not be used in patients with cardiovascular disease.
Obesity and excess weight are escalating public health concerns because they increase the prevalence of associated conditions such as diabetes mellitus and the risk of premature death.
1
,
2
More than 80% of even highly motivated patients are unable to achieve weight loss with dietary and lifestyle modifications alone.
3
Sibutramine is a norepinephrine and serotonin reuptake inhibitor that was approved for weight management in patients who are unable to lose weight by means of diet and exercise alone. Sibutramine induces satiety (resulting in reduced food intake) and an increase in energy expenditure.
4
,
5
In some patients, sibutramine increases blood pressure, pulse . . . |
|---|---|
| AbstractList | The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established.BACKGROUNDThe long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established.We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death).METHODSWe enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death).The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased.RESULTSThe mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased.Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)CONCLUSIONSSubjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.) The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.) Background The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. Methods We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). Results The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. Conclusions Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832 .) BACKGROUND: The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS: We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). RESULTS: The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. CONCLUSIONS: Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.) In this clinical trial, the appetite suppressant sibutramine as compared with placebo resulted in modest weight loss but also in an unexpected increase in the risk of nonfatal myocardial infarction and stroke (a finding limited to patients with preexisting cardiovascular disease). Sibutramine should not be used in patients with cardiovascular disease. Obesity and excess weight are escalating public health concerns because they increase the prevalence of associated conditions such as diabetes mellitus and the risk of premature death. 1 , 2 More than 80% of even highly motivated patients are unable to achieve weight loss with dietary and lifestyle modifications alone. 3 Sibutramine is a norepinephrine and serotonin reuptake inhibitor that was approved for weight management in patients who are unable to lose weight by means of diet and exercise alone. Sibutramine induces satiety (resulting in reduced food intake) and an increase in energy expenditure. 4 , 5 In some patients, sibutramine increases blood pressure, pulse . . . |
| Author | Shepherd, Gillian M Coutinho, Walmir Finer, Nick Sharma, Arya M James, W. Philip T Caterson, Ian D Van Gaal, Luc F Maggioni, Aldo P Torp-Pedersen, Christian Rode, Richard A Renz, Cheryl L |
| Author_xml | – sequence: 1 givenname: W. Philip T surname: James fullname: James, W. Philip T – sequence: 2 givenname: Ian D surname: Caterson fullname: Caterson, Ian D – sequence: 3 givenname: Walmir surname: Coutinho fullname: Coutinho, Walmir – sequence: 4 givenname: Nick surname: Finer fullname: Finer, Nick – sequence: 5 givenname: Luc F surname: Van Gaal fullname: Van Gaal, Luc F – sequence: 6 givenname: Aldo P surname: Maggioni fullname: Maggioni, Aldo P – sequence: 7 givenname: Christian surname: Torp-Pedersen fullname: Torp-Pedersen, Christian – sequence: 8 givenname: Arya M surname: Sharma fullname: Sharma, Arya M – sequence: 9 givenname: Gillian M surname: Shepherd fullname: Shepherd, Gillian M – sequence: 10 givenname: Richard A surname: Rode fullname: Rode, Richard A – sequence: 11 givenname: Cheryl L surname: Renz fullname: Renz, Cheryl L |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23175374$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20818901$$D View this record in MEDLINE/PubMed |
| BookMark | eNp10U1v1DAQBmALFdFt4cgVRUgVp4A_4jg5otXypcIKFc7W2BkvXiV2sZNF_HuMditEpfpiH5535Jm5IGchBiTkOaOvGZXtmy-bT58jMEoFY80jsmJSiLppaHtGVpTyrm5UL87JRc57Wg5r-ifknNOOdT1lK_J14xzauYquuvFmmRNMPmAVQ7WGNPh4gGyXEVK1XWYbJ8yVD9X2gOkX-t2PuYIwVFuDGaubxexLpfyUPHYwZnx2ui_J93ebb-sP9fX2_cf12-vaSq7meug6PjDgwJXEwSlA1cnWtAoEN870Q6eGwUArOTpkAxWttYgGFFClnHXikvBj3dHjDnVMxusD1xH88b2MOw1WG9Sct51WvWxYCb06hm5T_LlgnvXks8VxhIBxyVrJhnKuWFvky3tyH5cUSkdaNb2QkvWqoBcntJgJB32b_ATpt76bbwFXJ1DmCKNLEKzP_5xgSgrVFCeOzqaYc0KnrZ9h9jGUjfhRM6r_blv_t-2Squ-l7go_5E-_maasA-6nB9wfKZm1yA |
| CODEN | NEJMAG |
| CitedBy_id | crossref_primary_10_1016_j_bpg_2014_07_015 crossref_primary_10_1517_14656566_2011_591382 crossref_primary_10_1056_NEJMc1509759 crossref_primary_10_1161_CIR_0000000000000426 crossref_primary_10_1586_ers_12_78 crossref_primary_10_1208_s12249_021_01946_7 crossref_primary_10_1007_s00108_021_01159_x crossref_primary_10_1080_14740338_2020_1806234 crossref_primary_10_1124_pr_117_014803 crossref_primary_10_1007_s11883_015_0551_4 crossref_primary_10_1007_s13556_012_0003_1 crossref_primary_10_1016_j_giec_2011_02_006 crossref_primary_10_1016_j_yend_2011_06_052 crossref_primary_10_1007_s12020_013_9983_1 crossref_primary_10_5124_jkma_2011_54_4_409 crossref_primary_10_1590_S1518_8787_2016050006208 crossref_primary_10_1016_j_drudis_2013_08_015 crossref_primary_10_1007_s00414_023_03147_2 crossref_primary_10_1161_CIRCOUTCOMES_111_964072 crossref_primary_10_3389_fendo_2023_1236370 crossref_primary_10_1002_jbt_21516 crossref_primary_10_1007_s00125_013_2959_0 crossref_primary_10_2146_ajhp100638 crossref_primary_10_1007_s12020_014_0192_3 crossref_primary_10_1160_TH14_06_0513 crossref_primary_10_3390_metabo12030244 crossref_primary_10_1080_19371918_2018_1482252 crossref_primary_10_1517_14740338_2012_675326 crossref_primary_10_1016_j_fct_2018_10_051 crossref_primary_10_1016_j_bbamcr_2015_10_014 crossref_primary_10_1038_s41392_022_01149_x crossref_primary_10_2165_11601710_000000000_00000 crossref_primary_10_1080_14740338_2016_1194825 crossref_primary_10_1161_CIRCULATIONAHA_111_028381 crossref_primary_10_1177_102490791302000107 crossref_primary_10_1038_kisup_2012_62 crossref_primary_10_1097_FJC_0b013e31822eae22 crossref_primary_10_1186_s13578_023_01091_7 crossref_primary_10_1177_1934578X241292937 crossref_primary_10_15406_jdmdc_2015_02_00027 crossref_primary_10_1177_2042098613489721 crossref_primary_10_1155_2013_434706 crossref_primary_10_1371_journal_pone_0136915 crossref_primary_10_1097_MD_0000000000018060 crossref_primary_10_1007_s11419_020_00564_5 crossref_primary_10_1016_j_ijcard_2017_11_072 crossref_primary_10_1155_2011_984245 crossref_primary_10_1080_03007995_2016_1271315 crossref_primary_10_1007_s40265_013_0039_x crossref_primary_10_1007_s00213_014_3688_x crossref_primary_10_1038_s41366_018_0176_0 crossref_primary_10_1038_s41366_020_0544_4 crossref_primary_10_1111_j_1745_7599_2010_00587_x crossref_primary_10_1002_jcph_781 crossref_primary_10_1016_j_endoen_2014_11_001 crossref_primary_10_1111_j_1467_789X_2010_00828_x crossref_primary_10_3390_nu15061449 crossref_primary_10_1146_annurev_nutr_101220_114101 crossref_primary_10_1177_0269881117737401 crossref_primary_10_1016_j_talanta_2015_02_016 crossref_primary_10_1016_j_ahj_2020_07_008 crossref_primary_10_1111_dom_15062 crossref_primary_10_2165_11599000_000000000_00000 crossref_primary_10_2337_dcS15_3025 crossref_primary_10_3810_pgm_2013_11_2713 crossref_primary_10_1016_j_ecl_2020_05_009 crossref_primary_10_1186_s12906_021_03450_8 crossref_primary_10_3390_pr11082337 crossref_primary_10_1373_clinchem_2017_272815 crossref_primary_10_2165_11596680_000000000_00000 crossref_primary_10_1016_j_eprac_2024_09_004 crossref_primary_10_1007_s00125_012_2584_3 crossref_primary_10_3390_ph3123494 crossref_primary_10_1517_14740338_2015_995088 crossref_primary_10_1016_j_rcro_2025_100289 crossref_primary_10_2147_DMSO_S311359 crossref_primary_10_1007_s13181_012_0213_7 crossref_primary_10_1155_2021_8896932 crossref_primary_10_1590_1516_4446_2018_0004 crossref_primary_10_1016_j_obmed_2024_100552 crossref_primary_10_1155_2011_845148 crossref_primary_10_1007_s12020_016_0964_z crossref_primary_10_4137_MRI_S19362 crossref_primary_10_2147_DHPS_S305953 crossref_primary_10_1007_s13596_013_0107_5 crossref_primary_10_1080_14740338_2018_1437143 crossref_primary_10_1016_j_jacl_2024_01_007 crossref_primary_10_1093_nar_gkv1192 crossref_primary_10_14341_omet2015318_24 crossref_primary_10_14341_probl201258167_73 crossref_primary_10_1002_14651858_CD015861 crossref_primary_10_3358_shokueishi_59_93 crossref_primary_10_1007_s12170_010_0148_y crossref_primary_10_1002_jemt_22539 crossref_primary_10_1159_000503752 crossref_primary_10_1007_s11695_020_04986_3 crossref_primary_10_1038_hr_2011_173 crossref_primary_10_1155_2022_8387271 crossref_primary_10_1542_pir_2016_0210 crossref_primary_10_15429_jkomor_2021_21_2_105 crossref_primary_10_17795_jjnpp_34602 crossref_primary_10_2337_dc11_s255 crossref_primary_10_1016_j_obpill_2022_100024 crossref_primary_10_1152_ajpheart_00554_2015 crossref_primary_10_7570_kjo_2012_21_4_197 crossref_primary_10_1586_eog_11_18 crossref_primary_10_1007_s40265_015_0404_z crossref_primary_10_1111_dom_13958 crossref_primary_10_1111_cob_12651 crossref_primary_10_1016_j_biopha_2016_07_006 crossref_primary_10_1016_j_ypmed_2013_08_010 crossref_primary_10_5455_bcp_20140730034327 crossref_primary_10_1016_j_jacc_2024_08_007 crossref_primary_10_1016_j_xcrm_2021_100216 crossref_primary_10_1517_14740338_2014_909405 crossref_primary_10_1586_eem_11_50 crossref_primary_10_1016_j_cmet_2018_02_021 crossref_primary_10_1016_j_cjca_2011_01_016 crossref_primary_10_1097_MNH_0000000000000159 crossref_primary_10_1111_ijcp_12771 crossref_primary_10_1177_1474651412437501 crossref_primary_10_3810_pgm_2014_10_2817 crossref_primary_10_14260_jemds_2015_1931 crossref_primary_10_1177_1755738013485728 crossref_primary_10_1016_j_obpill_2022_100018 crossref_primary_10_1007_s00213_011_2615_7 crossref_primary_10_1038_ijo_2015_86 crossref_primary_10_1038_kisup_2012_52 crossref_primary_10_3390_neurolint13040049 crossref_primary_10_1007_s40264_015_0351_3 crossref_primary_10_1016_S2213_8587_17_30236_X crossref_primary_10_1210_endrev_bnab034 crossref_primary_10_1371_journal_pone_0039062 crossref_primary_10_1080_14740338_2016_1217989 crossref_primary_10_2217_clp_14_7 crossref_primary_10_1155_2011_636181 crossref_primary_10_1002_oby_20813 crossref_primary_10_1038_ijo_2012_144 crossref_primary_10_1016_j_mcna_2013_09_001 crossref_primary_10_14341_2071_8713_5192 crossref_primary_10_1007_s00129_016_4018_7 crossref_primary_10_1007_s11606_011_1828_0 crossref_primary_10_14341_probl201258134_38 crossref_primary_10_1016_j_gtc_2023_03_005 crossref_primary_10_1016_j_neuropharm_2012_01_017 crossref_primary_10_1097_MRR_0000000000000565 crossref_primary_10_1016_j_soard_2022_05_007 crossref_primary_10_1186_s12883_024_03772_3 crossref_primary_10_23907_2012_055 crossref_primary_10_3904_kjm_2018_93_6_501 crossref_primary_10_1155_2013_856793 crossref_primary_10_1007_s11906_013_0342_7 crossref_primary_10_1093_ajcn_nqx067 crossref_primary_10_1007_s40801_015_0021_x crossref_primary_10_2215_CJN_07040713 crossref_primary_10_3748_wjg_v20_i34_12182 crossref_primary_10_2337_dc11_s201 crossref_primary_10_1016_j_bmc_2014_11_018 crossref_primary_10_1177_2168479017742858 crossref_primary_10_1016_j_neuropharm_2011_10_008 crossref_primary_10_1001_jamanetworkopen_2018_3337 crossref_primary_10_1002_14651858_CD012436 crossref_primary_10_1111_dom_12657 crossref_primary_10_1016_j_jacc_2016_06_007 crossref_primary_10_15429_jkomor_2015_15_1_33 crossref_primary_10_36290_vnl_2018_171 crossref_primary_10_1111_obr_13224 crossref_primary_10_1016_j_metabol_2015_08_001 crossref_primary_10_1038_nrendo_2010_231 crossref_primary_10_1177_2042018811430839 crossref_primary_10_1016_j_crbiot_2024_100259 crossref_primary_10_1002_oby_20996 crossref_primary_10_1111_jcpt_12177 crossref_primary_10_5937_PsihDan2001113M crossref_primary_10_1007_s11102_011_0349_5 crossref_primary_10_1007_s11883_022_01027_5 crossref_primary_10_1097_HJH_0000000000001730 crossref_primary_10_1161_CIRCHEARTFAILURE_124_011518 crossref_primary_10_1053_j_ajkd_2020_08_016 crossref_primary_10_1590_S1516_44462012000100021 crossref_primary_10_1038_nm0211_157 crossref_primary_10_1016_j_phrs_2019_104341 crossref_primary_10_2337_dc13_0027 crossref_primary_10_1002_advs_202403442 crossref_primary_10_1161_HYPERTENSIONAHA_124_21361 crossref_primary_10_1186_s12906_015_0955_2 crossref_primary_10_1111_jne_12960 crossref_primary_10_2139_ssrn_4060714 crossref_primary_10_1111_obr_13112 crossref_primary_10_1080_00325481_2018_1435129 crossref_primary_10_1210_endrev_bnac015 crossref_primary_10_1007_s40290_017_0209_3 crossref_primary_10_22374_cjgim_v15i4_394 crossref_primary_10_1007_s10741_024_10410_0 crossref_primary_10_1053_j_gastro_2016_03_004 crossref_primary_10_1517_14656566_2014_890590 crossref_primary_10_1007_s11695_014_1276_0 crossref_primary_10_1002_cjoc_202400749 crossref_primary_10_2337_dc11_s205 crossref_primary_10_1002_oby_20627 crossref_primary_10_1016_j_cca_2013_11_007 crossref_primary_10_1016_j_lfs_2024_123171 crossref_primary_10_1016_j_atherosclerosis_2015_01_001 crossref_primary_10_1038_nrcardio_2011_58 crossref_primary_10_3389_fcell_2020_619888 crossref_primary_10_2217_pgs_11_137 crossref_primary_10_26599_NBE_2024_9290110 crossref_primary_10_1016_j_procs_2020_11_027 crossref_primary_10_3346_jkms_2018_33_e213 crossref_primary_10_1111_cob_12248 crossref_primary_10_2147_DMSO_S381652 crossref_primary_10_1007_s00423_011_0781_z crossref_primary_10_1111_obr_13326 crossref_primary_10_1016_j_psc_2011_08_006 crossref_primary_10_14341_omet201619_15 crossref_primary_10_1111_obr_13440 crossref_primary_10_1111_obr_13683 crossref_primary_10_4158_EP161365_GL crossref_primary_10_1007_s11096_021_01330_2 crossref_primary_10_1038_ijo_2013_90 crossref_primary_10_1111_j_1463_1326_2011_01554_x crossref_primary_10_2337_dc10_1859 crossref_primary_10_1097_HJH_0b013e328353e249 crossref_primary_10_3389_fpsyg_2019_00246 crossref_primary_10_1002_dta_1925 crossref_primary_10_1097_HJH_0000000000001757 crossref_primary_10_1007_s40264_014_0206_3 crossref_primary_10_1517_14656566_2014_946904 crossref_primary_10_1002_oby_20841 crossref_primary_10_1016_j_numecd_2015_01_011 crossref_primary_10_1016_j_pharmthera_2023_108549 crossref_primary_10_7856_kjcls_2016_27_1_137 crossref_primary_10_1038_ijo_2011_158 crossref_primary_10_1002_14651858_CD007654_pub4 crossref_primary_10_1007_s11883_018_0719_9 crossref_primary_10_1111_j_1365_2710_2011_01280_x crossref_primary_10_1111_j_1365_2710_2012_01347_x crossref_primary_10_1136_bjsports_2012_091396 crossref_primary_10_1016_j_trsl_2017_01_001 crossref_primary_10_1002_14651858_CD007654_pub5 crossref_primary_10_1161_CIRCULATIONAHA_111_039768 crossref_primary_10_1016_j_lfs_2022_120825 crossref_primary_10_1016_j_pharmthera_2018_11_002 crossref_primary_10_1210_endrev_bnad033 crossref_primary_10_3390_nu11092174 crossref_primary_10_1080_17446651_2024_2347258 crossref_primary_10_1016_j_clinthera_2019_06_005 crossref_primary_10_1186_s43094_020_00151_w crossref_primary_10_1002_dta_1980 crossref_primary_10_1111_j_1365_2710_2010_01217_x crossref_primary_10_3897_folmed_66_e121218 crossref_primary_10_1016_j_pharep_2014_11_012 crossref_primary_10_1016_S2213_8587_14_70004_X crossref_primary_10_1136_archdischild_2011_301127 crossref_primary_10_1111_bcp_12874 crossref_primary_10_1177_2040622315620180 crossref_primary_10_1177_1074248413501017 crossref_primary_10_1080_14656566_2024_2437525 crossref_primary_10_1016_S1957_2557_14_70772_2 crossref_primary_10_1056_NEJMoa1109220 crossref_primary_10_1097_CRD_0000000000000001 crossref_primary_10_17749_2070_4909_farmakoekonomika_2022_149 crossref_primary_10_1371_journal_pone_0178910 crossref_primary_10_3390_jcdd10080327 crossref_primary_10_33678_cor_2011_053 crossref_primary_10_1111_j_1753_0407_2012_00219_x crossref_primary_10_1039_D2AY00585A crossref_primary_10_1161_CIRCHEARTFAILURE_117_004551 crossref_primary_10_11301_jsfe_24659 crossref_primary_10_15406_mojddt_2018_02_00057 crossref_primary_10_1016_j_jand_2013_08_004 crossref_primary_10_1038_ijo_2012_93 crossref_primary_10_1007_s11892_017_0859_2 crossref_primary_10_1159_000478098 crossref_primary_10_1556_OH_2012_29317 crossref_primary_10_1007_s11695_023_06971_y crossref_primary_10_1111_dom_14618 crossref_primary_10_1039_D4AY00879K crossref_primary_10_1016_j_brat_2014_04_002 crossref_primary_10_1111_dom_12430 crossref_primary_10_1177_2040622314522848 crossref_primary_10_1002_dta_1964 crossref_primary_10_1097_HJH_0b013e328351c285 crossref_primary_10_1111_dom_13522 crossref_primary_10_1080_14656566_2019_1695779 crossref_primary_10_1002_cpt_1690 crossref_primary_10_1111_jcpt_13047 crossref_primary_10_3109_09637486_2015_1126567 crossref_primary_10_1016_j_metabol_2018_03_008 crossref_primary_10_1016_j_jacc_2021_05_035 crossref_primary_10_1111_bcpt_13467 crossref_primary_10_1517_14740338_2013_806481 crossref_primary_10_1016_S2213_8587_20_30038_3 crossref_primary_10_1016_j_mce_2015_09_005 crossref_primary_10_1038_hr_2011_85 crossref_primary_10_1093_eurheartj_sur014 crossref_primary_10_1111_cob_12159 crossref_primary_10_1093_ije_dyr045 crossref_primary_10_20945_2359_4292_2024_0422 crossref_primary_10_1080_07853890_2023_2203517 crossref_primary_10_1002_oby_21978 crossref_primary_10_2459_JCM_0000000000000492 crossref_primary_10_1056_NEJMoa2307563 crossref_primary_10_1002_oby_20407 crossref_primary_10_1038_ijo_2014_2 crossref_primary_10_1177_2040622313506730 crossref_primary_10_1080_14740338_2017_1259615 crossref_primary_10_1016_j_ycar_2010_12_010 crossref_primary_10_1177_0300985813492801 crossref_primary_10_4158_EP13263_RA crossref_primary_10_1093_cvr_cvac176 crossref_primary_10_1586_erc_11_83 crossref_primary_10_3389_fendo_2024_1364503 crossref_primary_10_1111_cob_12073 crossref_primary_10_1093_ndt_gfz064 crossref_primary_10_1038_ijo_2013_46 crossref_primary_10_1111_joim_12012 crossref_primary_10_4252_wjsc_v11_i12_1020 crossref_primary_10_1002_oby_23621 crossref_primary_10_1007_s40264_014_0238_8 crossref_primary_10_1111_j_1467_789X_2011_00981_x crossref_primary_10_1002_ams2_275 crossref_primary_10_1007_s11906_016_0683_0 crossref_primary_10_1016_S0001_4079_19_30885_4 crossref_primary_10_1177_2042018820938305 crossref_primary_10_3109_00498254_2012_706722 crossref_primary_10_1097_HJH_0b013e3283427c8b crossref_primary_10_1161_JAHA_122_029282 crossref_primary_10_1002_oby_20596 crossref_primary_10_1002_wsbm_1630 crossref_primary_10_1007_s11695_011_0514_y crossref_primary_10_1093_schbul_sbu030 crossref_primary_10_1016_j_ejim_2017_07_018 crossref_primary_10_1016_j_endonu_2014_11_002 crossref_primary_10_1161_JAHA_113_000395 crossref_primary_10_1016_j_jacc_2023_04_003 crossref_primary_10_1080_14656566_2018_1561867 crossref_primary_10_4236_fns_2016_74024 crossref_primary_10_2174_1871530323666230825140808 crossref_primary_10_1002_14651858_CD010665 crossref_primary_10_1016_j_mce_2015_05_033 crossref_primary_10_3233_CH_131765 crossref_primary_10_1111_dom_15530 crossref_primary_10_1007_s40265_018_1040_1 crossref_primary_10_1016_j_mayocp_2014_04_033 crossref_primary_10_1016_j_ijcard_2013_04_206 crossref_primary_10_1161_CIRCULATIONAHA_111_023499 crossref_primary_10_4103_ijem_ijem_442_23 crossref_primary_10_1016_j_dsx_2010_11_001 crossref_primary_10_3904_kjm_2013_84_5_624 crossref_primary_10_1080_14656566_2019_1571041 crossref_primary_10_1080_15563650_2025_2452297 crossref_primary_10_1159_000496564 crossref_primary_10_5863_1551_6776_17_1_45 crossref_primary_10_26442_SG28964 crossref_primary_10_1007_s11906_020_1027_7 crossref_primary_10_1016_j_forsciint_2022_111350 crossref_primary_10_17795_ijpbs_2445 crossref_primary_10_1007_s40290_016_0159_1 crossref_primary_10_1530_EJE_11_1068 crossref_primary_10_3109_09513590_2011_588745 crossref_primary_10_4093_dmj_2012_36_1_13 crossref_primary_10_1016_j_cmet_2011_06_014 crossref_primary_10_15406_emij_2017_05_00135 crossref_primary_10_3390_antiox12081549 crossref_primary_10_2165_11584800_000000000_00000 crossref_primary_10_1038_aps_2011_153 crossref_primary_10_1186_s13098_023_01233_4 crossref_primary_10_1038_nrdp_2018_14 crossref_primary_10_1016_j_beem_2013_04_012 crossref_primary_10_1080_14737175_2023_2273392 crossref_primary_10_1111_dom_15515 crossref_primary_10_1002_14651858_CD009339_pub2 crossref_primary_10_1016_j_metabol_2017_11_020 crossref_primary_10_1111_joim_12051 crossref_primary_10_1002_dmrr_3594 crossref_primary_10_3389_fphar_2023_1182937 crossref_primary_10_1155_2011_179674 crossref_primary_10_1016_j_suc_2020_12_012 crossref_primary_10_1124_pr_108_000869 crossref_primary_10_1155_2013_498935 crossref_primary_10_1097_SLA_0b013e318251e92b crossref_primary_10_3389_fendo_2018_00442 crossref_primary_10_1016_j_diabres_2012_02_012 crossref_primary_10_1111_j_1753_0407_2010_00104_x crossref_primary_10_1007_s40273_015_0300_0 crossref_primary_10_1097_MED_0b013e32834a8726 crossref_primary_10_1177_2040622313494986 crossref_primary_10_1002_14651858_CD010281_pub2 crossref_primary_10_1016_j_tem_2019_09_004 crossref_primary_10_1038_ejcn_2017_95 crossref_primary_10_1002_oby_20394 crossref_primary_10_3390_molecules22101795 crossref_primary_10_1016_j_bone_2014_01_022 crossref_primary_10_1021_acs_jmedchem_3c00067 crossref_primary_10_1097_MJT_0000000000001524 crossref_primary_10_1177_0960327112468907 crossref_primary_10_1517_14656566_2015_1041505 crossref_primary_10_56121_2181_3612_2023_2_04_08 crossref_primary_10_1371_journal_pone_0240030 crossref_primary_10_1097_CP9_0000000000000114 crossref_primary_10_1016_j_numecd_2013_12_009 crossref_primary_10_1002_bab_1432 crossref_primary_10_1007_s11695_018_3285_x crossref_primary_10_1161_CIR_0000000000001168 crossref_primary_10_1038_ijo_2012_26 crossref_primary_10_1007_s40264_019_00812_7 crossref_primary_10_1155_2013_541689 crossref_primary_10_1530_EJE_18_1021 crossref_primary_10_2217_pgs_10_203 crossref_primary_10_1016_j_ijbiomac_2023_125374 crossref_primary_10_1080_13543784_2016_1221925 crossref_primary_10_1016_j_tifs_2021_03_042 crossref_primary_10_4070_kcj_2013_43_9_632 crossref_primary_10_1016_j_ecl_2020_02_007 crossref_primary_10_1056_NEJMoa1808721 crossref_primary_10_1111_nyas_12004 crossref_primary_10_1038_ncb2867 crossref_primary_10_1155_2011_432607 crossref_primary_10_1097_HJH_0000000000000473 crossref_primary_10_1016_j_ahj_2015_01_007 crossref_primary_10_1016_S1957_2557_10_70135_8 crossref_primary_10_1016_j_yhbeh_2014_03_009 crossref_primary_10_1590_0004_2730000002825 crossref_primary_10_1016_j_talanta_2020_120788 crossref_primary_10_1161_CIR_0b013e3182a5cfb3 crossref_primary_10_1517_13543784_2011_630660 crossref_primary_10_1111_dom_13125 crossref_primary_10_14341_7928 crossref_primary_10_1002_oby_22676 crossref_primary_10_1111_1541_4337_12611 crossref_primary_10_1016_j_nupar_2022_09_001 crossref_primary_10_3390_molecules29040765 crossref_primary_10_1007_BF03261960 crossref_primary_10_1007_s11886_023_02016_z crossref_primary_10_1017_S1461145711000460 crossref_primary_10_2165_11592040_000000000_00000 crossref_primary_10_1055_s_0041_1731035 crossref_primary_10_1093_bmb_ldr002 crossref_primary_10_1002_agm2_12300 crossref_primary_10_1016_j_cjca_2010_12_054 crossref_primary_10_1111_j_1758_8111_2011_00023_x crossref_primary_10_1016_j_dsx_2019_05_004 crossref_primary_10_3390_molecules30061372 crossref_primary_10_2174_1871530319666181217123357 crossref_primary_10_1530_EJE_21_0972 crossref_primary_10_1159_000335352 crossref_primary_10_1002_bies_201200053 crossref_primary_10_7326_M19_3781 crossref_primary_10_1039_D0FO02185G crossref_primary_10_1590_0102_311x00124817 crossref_primary_10_14341_omet2017218_23 crossref_primary_10_1002_dmrr_2349 crossref_primary_10_3390_md19020091 crossref_primary_10_4062_biomolther_2015_033 crossref_primary_10_1016_j_eatbeh_2013_10_019 crossref_primary_10_1002_oby_20122 crossref_primary_10_1016_j_rmclc_2015_09_006 crossref_primary_10_1021_acs_jmedchem_8b01693 crossref_primary_10_1016_j_annepidem_2012_01_001 crossref_primary_10_6118_jmm_2014_20_3_90 crossref_primary_10_1016_j_taap_2016_11_003 crossref_primary_10_3390_nu15030656 crossref_primary_10_1155_2013_174782 crossref_primary_10_1093_eurjpc_zwad280 crossref_primary_10_1002_pdi_1717 crossref_primary_10_1016_j_cct_2017_06_004 crossref_primary_10_1016_j_fbio_2024_105515 crossref_primary_10_1038_s41569_020_00465_5 crossref_primary_10_1016_j_tem_2012_01_002 crossref_primary_10_1172_JCI129195 crossref_primary_10_1038_s41598_020_71249_7 crossref_primary_10_1186_s13098_019_0468_0 crossref_primary_10_3389_fnins_2020_00151 crossref_primary_10_1016_j_forsciint_2011_12_004 crossref_primary_10_1016_j_ahj_2023_04_012 crossref_primary_10_1111_j_1467_789X_2010_00846_x crossref_primary_10_1016_j_ejphar_2017_05_051 crossref_primary_10_1016_j_mmm_2024_01_001 crossref_primary_10_1038_nrgastro_2011_165 crossref_primary_10_1080_19440049_2012_706834 crossref_primary_10_1038_nrd_2016_31 crossref_primary_10_2217_clp_11_65 crossref_primary_10_1007_s00406_014_0522_8 crossref_primary_10_1093_ehjcvp_pvx014 crossref_primary_10_1248_bpb_35_568 crossref_primary_10_1016_j_ejphar_2018_10_009 crossref_primary_10_1111_jne_12287 crossref_primary_10_1093_ehjqcco_qcae063 crossref_primary_10_1111_bcp_14179 crossref_primary_10_3109_07853890_2010_541490 crossref_primary_10_1586_erc_10_22 crossref_primary_10_3945_ajcn_114_086470 crossref_primary_10_1016_j_jacc_2023_11_032 crossref_primary_10_1016_S1516_4446_12_70021_1 crossref_primary_10_1371_journal_pone_0059121 crossref_primary_10_4162_nrp_2019_13_6_461 crossref_primary_10_1016_S2213_8587_24_00098_6 crossref_primary_10_1080_14728214_2017_1269744 crossref_primary_10_1159_000488880 crossref_primary_10_23736_S0391_1977_20_03179_X crossref_primary_10_14341_omet12663 crossref_primary_10_1002_biot_202000013 crossref_primary_10_1210_clinem_dgab421 crossref_primary_10_1007_s40265_018_0946_y crossref_primary_10_1007_s11883_021_00961_0 crossref_primary_10_1111_j_1747_0080_2011_01523_x crossref_primary_10_1113_jphysiol_2014_272955 crossref_primary_10_1155_2010_789280 crossref_primary_10_5582_ddt_2016_01014 crossref_primary_10_1007_s10337_018_3502_8 crossref_primary_10_1590_S1516_44462011000200004 crossref_primary_10_1517_14728214_2011_609168 crossref_primary_10_1080_14656566_2024_2428371 crossref_primary_10_1080_14740338_2017_1247807 crossref_primary_10_1093_ehjcvp_pvw029 crossref_primary_10_7759_cureus_21650 crossref_primary_10_1111_ijcp_12384 crossref_primary_10_1038_nrendo_2017_122 crossref_primary_10_1039_c3ay41872c crossref_primary_10_2146_ajhp140574 crossref_primary_10_1016_j_celrep_2019_07_101 crossref_primary_10_1016_j_neuropharm_2012_04_001 crossref_primary_10_1161_CIRCULATIONAHA_111_022541 crossref_primary_10_1038_ijo_2014_211 crossref_primary_10_1186_s12302_020_00333_6 crossref_primary_10_1177_1074248416639719 crossref_primary_10_1016_j_obpill_2023_100071 crossref_primary_10_1080_17512433_2016_1232164 crossref_primary_10_3389_fpsyt_2023_1153648 crossref_primary_10_3390_ph4010001 crossref_primary_10_1016_j_jnma_2024_09_004 crossref_primary_10_1093_eurheartj_eht101 crossref_primary_10_3390_jcm13144151 crossref_primary_10_1038_oby_2011_51 crossref_primary_10_1097_MD_0000000000000725 crossref_primary_10_5812_jjnpp_34602 crossref_primary_10_1016_j_orcp_2023_05_009 crossref_primary_10_1002_med_21476 crossref_primary_10_1177_0884533617713189 crossref_primary_10_1016_j_procs_2021_10_038 crossref_primary_10_1007_s00108_011_2811_x crossref_primary_10_1016_j_ycar_2011_01_121 crossref_primary_10_1517_14728214_2011_531700 crossref_primary_10_1017_S0029665122002695 crossref_primary_10_1007_s11883_013_0380_2 crossref_primary_10_1186_1741_7015_12_149 crossref_primary_10_3389_fnins_2021_621356 crossref_primary_10_1007_s40256_019_00328_6 crossref_primary_10_1038_s41573_021_00337_8 crossref_primary_10_1016_j_rmu_2015_04_002 crossref_primary_10_1155_2012_435702 crossref_primary_10_4158_EP11105_RA crossref_primary_10_1007_s11906_013_0334_7 crossref_primary_10_1002_clc_22304 crossref_primary_10_1016_j_artere_2017_06_003 crossref_primary_10_18786_2072_0505_2021_49_029 crossref_primary_10_4093_jkd_2015_16_4_260 crossref_primary_10_1124_jpet_112_202895 crossref_primary_10_1056_NEJMe1007993 crossref_primary_10_3389_fphys_2018_00122 crossref_primary_10_1016_j_jtumed_2016_03_009 crossref_primary_10_1016_j_molmet_2014_01_005 crossref_primary_10_1097_HJH_0b013e3283537347 crossref_primary_10_1111_1753_0407_12123 crossref_primary_10_1111_jce_12111 crossref_primary_10_2146_ajhp140034 crossref_primary_10_1080_17446651_2023_2209176 crossref_primary_10_22141_2306_2436_12_2_2023_305 crossref_primary_10_1111_obr_12747 crossref_primary_10_1016_j_arteri_2017_06_002 crossref_primary_10_3389_fphar_2021_613837 crossref_primary_10_1097_MD_0000000000040364 crossref_primary_10_1186_s40608_017_0147_3 crossref_primary_10_1016_S1957_2557_12_70352_8 crossref_primary_10_1080_14656566_2020_1748599 crossref_primary_10_1161_HYPERTENSIONAHA_119_14240 crossref_primary_10_14341_omet2018153_70 crossref_primary_10_3389_fphar_2020_611361 crossref_primary_10_1016_j_ahj_2018_03_012 crossref_primary_10_1016_j_mmm_2021_10_012 crossref_primary_10_1080_14656566_2022_2104636 crossref_primary_10_1161_CIRCULATIONAHA_111_040139 crossref_primary_10_18325_jkmr_2023_33_3_33 crossref_primary_10_1007_s40265_015_0410_1 crossref_primary_10_1038_ijo_2013_205 crossref_primary_10_1161_STR_0000000000000024 crossref_primary_10_1002_pbc_23366 crossref_primary_10_1016_j_amjcard_2011_02_354 crossref_primary_10_1097_EDE_0000000000000428 crossref_primary_10_18325_jkmr_2020_30_4_89 crossref_primary_10_1136_bmjopen_2019_029426 crossref_primary_10_1097_HCO_0b013e3283642a4c crossref_primary_10_1155_2022_6852276 crossref_primary_10_1016_j_cjca_2014_11_010 crossref_primary_10_1002_phar_1277 crossref_primary_10_1177_1756283X12459413 crossref_primary_10_4155_cli_11_8 crossref_primary_10_1242_dmm_009621 crossref_primary_10_1038_ijo_2013_111 crossref_primary_10_1053_j_ajkd_2018_08_017 crossref_primary_10_1152_ajpheart_00492_2012 crossref_primary_10_1038_clpt_2011_82 crossref_primary_10_1016_j_jpba_2021_113948 crossref_primary_10_1038_clpt_2013_15 crossref_primary_10_1007_s40256_020_00428_8 crossref_primary_10_1038_oby_2011_337 crossref_primary_10_1080_01480545_2016_1236128 crossref_primary_10_1111_jce_12136 crossref_primary_10_1517_14740338_2015_994502 crossref_primary_10_1016_j_molmet_2020_01_008 crossref_primary_10_3810_pgm_2011_09_2475 crossref_primary_10_1586_ecp_13_13 crossref_primary_10_1080_15563650_2020_1822529 crossref_primary_10_1097_01_NPR_0000472248_28703_18 crossref_primary_10_1080_00325481_2015_1048181 crossref_primary_10_1172_JCI70338 crossref_primary_10_1038_oby_2011_330 crossref_primary_10_1016_j_amjmed_2016_02_009 crossref_primary_10_1016_j_jacc_2011_03_052 crossref_primary_10_1038_ijo_2013_225 crossref_primary_10_5124_jkma_2015_58_5_452 crossref_primary_10_1016_S0140_6736_10_62299_4 crossref_primary_10_3390_medsci10040056 crossref_primary_10_1016_j_ajp_2018_06_016 crossref_primary_10_1002_2211_5463_12024 |
| Cites_doi | 10.1016/S0140-6736(08)61171-X 10.1016/j.amjcard.2005.06.025 10.1056/NEJMoa066254 10.1016/j.clpt.2006.02.002 10.1177/009286150804200402 10.1093/eurheartj/ehm217 10.1056/NEJM199908053410604 10.1177/0269881108095195 10.1111/j.1467-789X.2007.00425.x 10.1136/bmj.39548.738368.BE 10.1001/jama.293.15.1868 10.1093/eurheartj/sui086 10.3945/ajcn.2008.26147 10.1093/eurheartj/ehn427 10.1136/jech.56.3.218 10.1056/NEJM199811053391902 10.1001/archinte.165.12.1410 10.1097/01.hjh.0000217838.49842.1e 10.1016/j.pcad.2009.06.001 10.1136/bmj.333.7572.794 10.1016/j.ahj.2005.03.006 10.1016/S0140-6736(86)91111-6 10.1056/NEJMoa066603 10.1093/ajcn/56.2.320 10.1056/NEJM198104163041602 10.1016/S0140-6736(02)09327-3 10.1146/annurev.nutr.21.1.323 10.1111/j.1467-789X.2009.00581.x 10.1016/S0140-6736(09)60318-4 10.1038/sj.ijo.0801035 |
| ContentType | Journal Article Web Resource |
| Contributor | Dendale, P Armstrong, P Zanella, M T Van Kuyk, M Phillips, P Van Gaal, L F Jordan, J Halmy, L Narkiewicz, K Peiffer, F Caterson, I D Pocock, S Gonzalez, C Moses, R Kerr, D de Godoy Matos, A Fernando Carey, D Cerny, P Singh, B Pascual, J Coucke, F Dagenais, G Bogaty, P Singleton Jeffries, W Sherman, D Milagres, R Fabbri, G Cifkova, R Havranek, P Toubro, S Santini, F Proietto, J Shaw, J Martens, F Cepelak, V Lefkovits, J Costa e Forti, A Swedberg, K Kutnowski, M de Albuquerque, D Campos Muls, E Appolinario, J Hainer, V Wollaert, B Roberts-Thomson, P Jouret, G Penninckx, H Sharma, A M Kolanowski, J Brophy, J Colquhoun, D Hancu, N Jansa, P Stuckey, B Wilding, J Campbell, L Torp-Pedersen, C Ostergren, J Sleight, P Hildebrandt, P Suplicy, H Lacerda Roberts, D Van Crombrugge, P Gross, J Luiz Halpern, A Scheen, A Boland, J Vaerenberg, M Bednarova, J James, W P T Galli, M Van Cleemput, J Payer, J Karrasch, J Zannad, F Homza, M Marks, S Simpson, R Kerr Saraiva, J F Mann, J Marks, J Repetto, G Brohet, C Schoors, D Scherbaum, W A Gerstman, M Verhaegen, A Drexler, H Ferrannini, E Pepin SCHEEN, André |
| Contributor_xml | – sequence: 1 givenname: W P T surname: James fullname: James, W P T – sequence: 1 fullname: SCHEEN, André – sequence: 2 givenname: I D surname: Caterson fullname: Caterson, I D – sequence: 3 givenname: W surname: Coutinho fullname: Coutinho, W – sequence: 4 givenname: N surname: Finer fullname: Finer, N – sequence: 5 givenname: L F surname: Van Gaal fullname: Van Gaal, L F – sequence: 6 givenname: A P surname: Maggioni fullname: Maggioni, A P – sequence: 7 givenname: A M surname: Sharma fullname: Sharma, A M – sequence: 8 givenname: C surname: Torp-Pedersen fullname: Torp-Pedersen, C – sequence: 9 givenname: C surname: Pepine fullname: Pepine, C – sequence: 10 givenname: S surname: Pocock fullname: Pocock, S – sequence: 11 givenname: H surname: Drexler fullname: Drexler, H – sequence: 12 givenname: K surname: Swedberg fullname: Swedberg, K – sequence: 13 givenname: P surname: Sleight fullname: Sleight, P – sequence: 14 givenname: P surname: Armstrong fullname: Armstrong, P – sequence: 15 givenname: D surname: Kerr fullname: Kerr, D – sequence: 16 givenname: G surname: Dagenais fullname: Dagenais, G – sequence: 17 givenname: J surname: Brophy fullname: Brophy, J – sequence: 18 givenname: A surname: Avezum fullname: Avezum, A – sequence: 19 givenname: P surname: Bogaty fullname: Bogaty, P – sequence: 20 givenname: G surname: Fabbri fullname: Fabbri, G – sequence: 21 givenname: M surname: Galli fullname: Galli, M – sequence: 22 givenname: P surname: Hildebrandt fullname: Hildebrandt, P – sequence: 23 givenname: J surname: Mann fullname: Mann, J – sequence: 24 givenname: J surname: Ostergren fullname: Ostergren, J – sequence: 25 givenname: D surname: Sherman fullname: Sherman, D – sequence: 26 givenname: F surname: Zannad fullname: Zannad, F – sequence: 27 givenname: D surname: Colquhoun fullname: Colquhoun, D – sequence: 28 givenname: G surname: Hollanders fullname: Hollanders, G – sequence: 29 givenname: A surname: Costa e Forti fullname: Costa e Forti, A – sequence: 30 givenname: R surname: Cifkova fullname: Cifkova, R – sequence: 31 givenname: S surname: Toubro fullname: Toubro, S – sequence: 32 givenname: O surname: Ziegler fullname: Ziegler, O – sequence: 33 givenname: W A surname: Scherbaum fullname: Scherbaum, W A – sequence: 34 givenname: J surname: Jordan fullname: Jordan, J – sequence: 35 givenname: L surname: Halmy fullname: Halmy, L – sequence: 36 givenname: E surname: Ferrannini fullname: Ferrannini, E – sequence: 37 givenname: F surname: Santini fullname: Santini, F – sequence: 38 givenname: C surname: Gonzalez fullname: Gonzalez, C – sequence: 39 givenname: K surname: Narkiewicz fullname: Narkiewicz, K – sequence: 40 givenname: N surname: Hancu fullname: Hancu, N – sequence: 41 givenname: J surname: Payer fullname: Payer, J – sequence: 42 givenname: J surname: Pascual fullname: Pascual, J – sequence: 43 givenname: J surname: Wilding fullname: Wilding, J – sequence: 44 givenname: L surname: Campbell fullname: Campbell, L – sequence: 45 givenname: D surname: Carey fullname: Carey, D – sequence: 46 givenname: M surname: Gerstman fullname: Gerstman, M – sequence: 47 givenname: J surname: Karrasch fullname: Karrasch, J – sequence: 48 givenname: J surname: Lefkovits fullname: Lefkovits, J – sequence: 49 givenname: J surname: Marks fullname: Marks, J – sequence: 50 givenname: S surname: Marks fullname: Marks, S – sequence: 51 givenname: R surname: Moses fullname: Moses, R – sequence: 52 givenname: P surname: Phillips fullname: Phillips, P – sequence: 53 givenname: J surname: Proietto fullname: Proietto, J – sequence: 54 givenname: D surname: Roberts fullname: Roberts, D – sequence: 55 givenname: P surname: Roberts-Thomson fullname: Roberts-Thomson, P – sequence: 56 givenname: J surname: Shaw fullname: Shaw, J – sequence: 57 givenname: R surname: Simpson fullname: Simpson, R – sequence: 58 givenname: B surname: Singh fullname: Singh, B – sequence: 59 givenname: W surname: Singleton Jeffries fullname: Singleton Jeffries, W – sequence: 60 givenname: B surname: Stuckey fullname: Stuckey, B – sequence: 61 givenname: J surname: Boland fullname: Boland, J – sequence: 62 givenname: C surname: Brohet fullname: Brohet, C – sequence: 63 givenname: F surname: Coucke fullname: Coucke, F – sequence: 64 givenname: P surname: Dendale fullname: Dendale, P – sequence: 65 givenname: G surname: Jouret fullname: Jouret, G – sequence: 66 givenname: J surname: Kolanowski fullname: Kolanowski, J – sequence: 67 givenname: M surname: Kutnowski fullname: Kutnowski, M – sequence: 68 givenname: F surname: Martens fullname: Martens, F – sequence: 69 givenname: E surname: Muls fullname: Muls, E – sequence: 70 givenname: F surname: Peiffer fullname: Peiffer, F – sequence: 71 givenname: H surname: Penninckx fullname: Penninckx, H – sequence: 72 givenname: A surname: Scheen fullname: Scheen, A – sequence: 73 givenname: D surname: Schoors fullname: Schoors, D – sequence: 74 givenname: M surname: Vaerenberg fullname: Vaerenberg, M – sequence: 75 givenname: J surname: Van Cleemput fullname: Van Cleemput, J – sequence: 76 givenname: P surname: Van Crombrugge fullname: Van Crombrugge, P – sequence: 77 givenname: M surname: Van Kuyk fullname: Van Kuyk, M – sequence: 78 givenname: A surname: Verhaegen fullname: Verhaegen, A – sequence: 79 givenname: B surname: Wollaert fullname: Wollaert, B – sequence: 80 givenname: D Campos surname: de Albuquerque fullname: de Albuquerque, D Campos – sequence: 81 givenname: J surname: Appolinario fullname: Appolinario, J – sequence: 82 givenname: A Fernando surname: de Godoy Matos fullname: de Godoy Matos, A Fernando – sequence: 83 givenname: J Luiz surname: Gross fullname: Gross, J Luiz – sequence: 84 givenname: A surname: Halpern fullname: Halpern, A – sequence: 85 givenname: J F surname: Kerr Saraiva fullname: Kerr Saraiva, J F – sequence: 86 givenname: R surname: Milagres fullname: Milagres, R – sequence: 87 givenname: G surname: Repetto fullname: Repetto, G – sequence: 88 givenname: H Lacerda surname: Suplicy fullname: Suplicy, H Lacerda – sequence: 89 givenname: M T surname: Zanella fullname: Zanella, M T – sequence: 90 givenname: J surname: Bednarova fullname: Bednarova, J – sequence: 91 givenname: V surname: Cepelak fullname: Cepelak, V – sequence: 92 givenname: P surname: Cerny fullname: Cerny, P – sequence: 93 givenname: V surname: Hainer fullname: Hainer, V – sequence: 94 givenname: P surname: Havranek fullname: Havranek, P – sequence: 95 givenname: M surname: Homza fullname: Homza, M – sequence: 96 givenname: P surname: Jansa fullname: Jansa, P |
| Copyright | Copyright © 2010 Massachusetts Medical Society. All rights reserved. 2015 INIST-CNRS |
| Copyright_xml | – notice: Copyright © 2010 Massachusetts Medical Society. All rights reserved. – notice: 2015 INIST-CNRS |
| CorporateAuthor | SCOUT Investigators |
| CorporateAuthor_xml | – name: SCOUT Investigators |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 Q33 |
| DOI | 10.1056/NEJMoa1003114 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database (ProQuest) ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials - QC Biological Science Collection eLibrary ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library SciTech Premium Collection New England Journal of Medicine Biological Sciences Consumer Health Database Healthcare Administration Database (ProQuest) Medical Database Psychology Database Research Library Science Database Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic Université de Liège - Open Repository and Bibliography (ORBI) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-4406 |
| EndPage | 917 |
| ExternalDocumentID | oai_orbi_ulg_ac_be_2268_79541 2128783241 20818901 23175374 10_1056_NEJMoa1003114 NJ201009023631005 |
| Genre | Original Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | - 0R 0WA 123 186 1AW 1KJ 1VV 29N 2KS 2WC 34G 39C 3O- 3V. 4 4.4 53G 55 5D0 5RE 68V 7FN 7RV 7X7 85S 8AO 8C1 8FE 8FH 8FI 8RP AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AASXA AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQES ABQIJ ABUFD ABUWG ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACRZS ACVYA ADBBV ADCBC AENEX AETEA AFDAS AFFNX AFHKK AFKRA AGNAY AHMBA AHVBC AIKQT AJJEV AJYGW ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI AZQEC BBAFP BBNVY BCR BCU BENPR BES BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C45 CJ0 CO CS3 DCD DU5 DWQXO DZ EBS EJD ET EX3 F20 F5P FD8 FM. FYUFA G8K GJ GNUQQ GUQSH H13 HCIFZ HZ IH2 K-O K78 KM KOO L7B LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC MVM N9A NEJ O0- O9- OHT OK1 OMK OVD P-O P2P PADUT PCD PEA PQEST PQQKQ PQUKI PRINS PROAC PSQYO QJJ RHI RWL RXW S10 S6N SJFOW SJN TAE TAF TN5 TWZ U1N UCV UKR UMD UQL VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZGI ZHY ZKB ZR0 ZXP --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 1CY 36B 6TJ AAMNW AAYXX ABBLC ABCQX ABDPE ABDQB ABJNI ACKOT ACPFK ADRHT ADUKH ADXHL AERZD AFOSN AGFXO AGHSJ ALIPV BYPQX CCPQU CITATION HF~ HMCUK HZ~ N4W NAPCQ PHGZM PHGZT PSYQQ TEORI TUQ UKHRP XOL YFH YR2 YR5 YYP ZCA ZVN ~KM 41~ 8WZ 9M8 A6W AAQOH AAUTI ABEFU ACPVT ACTDY AFFDN AJUXI D0S FA8 IQODW J5H LPU MQT NHB PJZUB PPXIY PQGLB QZG SKT UBX WHG YHZ YQI YQJ YYQ CGR CUY CVF ECM EIF NPM R.3 UIG VXZ YIF YIN Z5M 7XB BEC K0Y PKEHL Q9U 7X8 Q33 |
| ID | FETCH-LOGICAL-c527t-d882d1a2a275edf7ae7856b67a32bfb9d87ddba652efe1d036cceeba7a077fcf3 |
| IEDL.DBID | 7X7 |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Fri Jul 25 15:26:10 EDT 2025 Fri Jul 11 15:18:04 EDT 2025 Sat Aug 23 12:33:19 EDT 2025 Wed Feb 19 02:02:04 EST 2025 Mon Jul 21 09:14:34 EDT 2025 Tue Jul 01 02:36:46 EDT 2025 Thu Apr 24 23:01:49 EDT 2025 Wed Nov 11 00:33:08 EST 2020 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | Human Obesity Prognosis Serotonin Body weight Nutrition disorder Cardiovascular disease Corporal biometry Sibutramine Catecholamine Reuptake inhibitor Overweight Medicine Neurotransmitter Norepinephrine Anorectic Nutritional status |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c527t-d882d1a2a275edf7ae7856b67a32bfb9d87ddba652efe1d036cceeba7a077fcf3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-General Information-1 content type line 14 ObjectType-Feature-3 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 scopus-id:2-s2.0-77956284607 |
| OpenAccessLink | https://www.nejm.org/doi/pdf/10.1056/NEJMoa1003114?articleTools=true |
| PMID | 20818901 |
| PQID | 749355197 |
| PQPubID | 40644 |
| PageCount | 13 |
| ParticipantIDs | liege_orbi_v2_oai_orbi_ulg_ac_be_2268_79541 proquest_miscellaneous_754022716 proquest_journals_749355197 pubmed_primary_20818901 pascalfrancis_primary_23175374 crossref_citationtrail_10_1056_NEJMoa1003114 crossref_primary_10_1056_NEJMoa1003114 mms_nejm_10_1056_NEJMoa1003114 |
| ProviderPackageCode | DCD 7FN CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2010-09-02 |
| PublicationDateYYYYMMDD | 2010-09-02 |
| PublicationDate_xml | – month: 09 year: 2010 text: 2010-09-02 day: 02 |
| PublicationDecade | 2010 |
| PublicationPlace | Waltham, MA |
| PublicationPlace_xml | – name: Waltham, MA – name: United States – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationTitleAlternate | N Engl J Med |
| PublicationYear | 2010 |
| Publisher | Massachusetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society |
| References | r020 r021 r023 r019 (r014) 1994; 344 r013 r035 r036 r037 r016 (r011) 1996; 12 r031 r010 r032 r033 r012 r034 r006 r028 r007 r029 r008 r009 Mallinckrodt CH (r015) 2008; 42 r024 r003 r025 r004 r026 r005 Dattilo AM (r018) 1992; 56 r027 Lyznicki JM (r017) 2001; 63 20818908 - N Engl J Med. 2010 Sep 2;363(10):972-4 |
| References_xml | – ident: r029 doi: 10.1016/S0140-6736(08)61171-X – ident: r034 doi: 10.1016/j.amjcard.2005.06.025 – ident: r019 doi: 10.1056/NEJMoa066254 – volume: 12 start-page: 127 year: 1996 ident: r011 publication-title: Can J Cardiol – ident: r026 doi: 10.1016/j.clpt.2006.02.002 – volume: 42 start-page: 303 year: 2008 ident: r015 publication-title: Drug Inf J doi: 10.1177/009286150804200402 – ident: r008 doi: 10.1093/eurheartj/ehm217 – volume: 344 start-page: 1383 year: 1994 ident: r014 publication-title: Lancet – ident: r012 doi: 10.1056/NEJM199908053410604 – ident: r005 doi: 10.1177/0269881108095195 – ident: r006 doi: 10.1111/j.1467-789X.2007.00425.x – ident: r023 doi: 10.1136/bmj.39548.738368.BE – ident: r033 doi: 10.1001/jama.293.15.1868 – ident: r007 doi: 10.1093/eurheartj/sui086 – ident: r031 doi: 10.3945/ajcn.2008.26147 – ident: r024 doi: 10.1093/eurheartj/ehn427 – ident: r021 doi: 10.1136/jech.56.3.218 – ident: r013 doi: 10.1056/NEJM199811053391902 – ident: r025 doi: 10.1001/archinte.165.12.1410 – ident: r027 doi: 10.1097/01.hjh.0000217838.49842.1e – ident: r028 doi: 10.1016/j.pcad.2009.06.001 – ident: r004 doi: 10.1136/bmj.333.7572.794 – ident: r036 doi: 10.1016/j.ahj.2005.03.006 – ident: r009 doi: 10.1016/S0140-6736(86)91111-6 – ident: r020 doi: 10.1056/NEJMoa066603 – volume: 56 start-page: 320 year: 1992 ident: r018 publication-title: Am J Clin Nutr doi: 10.1093/ajcn/56.2.320 – ident: r016 doi: 10.1056/NEJM198104163041602 – ident: r010 doi: 10.1016/S0140-6736(02)09327-3 – ident: r003 doi: 10.1146/annurev.nutr.21.1.323 – ident: r037 doi: 10.1111/j.1467-789X.2009.00581.x – volume: 63 start-page: 2185 year: 2001 ident: r017 publication-title: Am Fam Physician – ident: r035 doi: 10.1016/S0140-6736(09)60318-4 – ident: r032 doi: 10.1038/sj.ijo.0801035 – reference: 20818908 - N Engl J Med. 2010 Sep 2;363(10):972-4 |
| RestrictionsOnAccess | restricted access |
| SSID | ssj0000149 |
| Score | 2.5555747 |
| Snippet | In this clinical trial, the appetite suppressant sibutramine as compared with placebo resulted in modest weight loss but also in an unexpected increase in the... The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have... Background The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular... BACKGROUND: The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular... |
| SourceID | liege proquest pubmed pascalfrancis crossref mms |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 905 |
| SubjectTerms | Aged Appetite Depressants - adverse effects Appetite Depressants - therapeutic use Biological and medical sciences Blood pressure Blood Pressure - drug effects Cardiovascular & respiratory systems Cardiovascular disease Cardiovascular Diseases - chemically induced Cardiovascular Diseases - complications Cardiovascular Diseases - epidemiology Cardiovascular Diseases - mortality complications/epidemiology Cyclobutanes - adverse effects Cyclobutanes - therapeutic use Diabetes Diabetes Mellitus, Type 2 - complications Double-Blind Method Endocrinologie, métabolisme & nutrition Endocrinology, metabolism & nutrition Female General aspects Heart failure Human health sciences Humans Hypertension Kaplan-Meier Estimate Male Medical sciences Metabolic diseases Middle Aged mortality Myocardial Infarction - chemically induced Myocardial Infarction - epidemiology Obesity Obesity - complications Obesity - drug therapy Overweight - complications Overweight - drug therapy Pharmacie, pharmacologie & toxicologie Pharmacy, pharmacology & toxicology Sciences de la santé humaine Stroke - chemically induced Stroke - epidemiology Systèmes cardiovasculaire & respiratoire therapeutic use |
| Title | Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects |
| URI | http://dx.doi.org/10.1056/NEJMoa1003114 https://www.ncbi.nlm.nih.gov/pubmed/20818901 https://www.proquest.com/docview/749355197 https://www.proquest.com/docview/754022716 http://orbi.ulg.ac.be/handle/2268/79541 |
| Volume | 363 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagKyEuiPIMbVc-IC4QNfHGcXJCZdWqQqLlVWlv1viFinaTstnl9zOTeBf2sFyiKLEcxTP2fPaMvo-x11UWiLWrSstJZtICAOdcVRVpJn0GJQD6dc_2eVVe3hQfZ3IWa3O6WFa5WRP7hdq1ls7IT1VBTOB5rd7f_UpJNIqSq1FB4z4bEXMZVXSpmfqHPSqi33iAFCk2MeSfktB8Czm5dF7shKTRnJLVGGkWi44KJaHDsQqDyMV-FNpHo4vH7FGEkfxssPshu-ebJ-zBp5gof8q-DKzEvA38GylaLWGBz3nb8OlOASq_Xq_w_33Hbxt-3RdJ026dQ-M4aQZ4jisLHdV0z9jNxfn36WUa1RNSK4VapQ6xs8tBgFDSu6DAq0qWplQwESaY2lXKOQOlFD743GEksxgwDSjIlAo2TJ6zg6Zt_EvGQTolra2tl6JwUhoQpvQVWAi1rIVI2LvNAGobqcVJ4WKu-xS3LPXOeCfszbb53cCpsa_h294aul2aW_1baOLC7u_X8x8arDZeI3ystKplkSdsjDbTjf-52NfdeMec248LAlEThQ2ONvbVcSp3eut4CePbtzgHKbECjW_X2ARhrxC480zYi8Er_nZNlIGIuV79t-sj9nCoSqjTTByzg9Vy7U8Q7KzMuHdpvFbTfMxGH86vPn_9A2uG_VM |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VRAIuiDemEPYAXMCqvfZ67QNCUFqltE15tFJvy6x3XbVK7BInIH4U_5FZ2wnkEG69Rc5oLO089tud8TcAz9OgcKxdqZ9EgfZjRIq5NI39QNgAE0Ty64btc5QMT-KPp-J0A34vvoVxbZWLnNgkalPl7o58S8aOCTzM5NvL774bGuWKq4sJGq1X7NtfP-nEVr_Z-0DmfcH57s7x9tDvhgr4ueBy5huClCZEjlwKawqJVqYi0YnEiOtCZyaVxmhMBLeFDQ0l-Jz2EY0SAymLvIhI7zXoxxGdZHrQf78z-vTlH76qDm93V1YdqSeBjC032r7C0AVRGK9sgv2xK4_T3jaZ1K41E2uyTtGO1ViPe5v9b_c23OqAK3vXetod2LDlXbh-2JXm78HnlgeZVQX76mZoTXFCz1lVsu2Vlld2NJ_RituanZfsqGnLdvcDDEvD3JQCyyiXucuh-j6cXMnSPoBeWZX2ETAURoo8z3IreGyE0Mh1YlPMschExrkHrxcLqPKOzNzN1BirpqguErWy3h68XIpftiwe6wRfNdZQ1VSfqx9cOfbt5vd8fKYwV9oqAqypkpmIQw8GZDNV2ovJOnWDFXMuX84dbIskCWwu7Ku65FGrpat7wJb_UtS7Ug6WtpqTCAFtzums68HD1iv-qnYkhYTyHv9X9TO4MTw-PFAHe6P9TbjZ9kRkfsCfQG82ndunBLVmetA5OINvVx1TfwBEbTxy |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVqq4IN6YQtgDcAEr9trrtQ8IoZaopdCCoFJu29mHUVFilzgB8dP4d8zaTiCHcOvNsldraZ6fd8bfADzNo9KzduVhlkQ6TBHJ5_I8DSPhIswQya5bts-T7PAsfTcW4y34vfwXxrdVLmNiG6htbfwZ-VCmngk8LuSw7LsiPh6MXl9-D_0AKV9oXU7T6Czk2P36SV9vzaujA1L1M85Hb7_sH4b9gIHQCC7noSV4aWPkyKVwtpToZC4ynUlMuC51YXNprcZMcFe62FKwN5RTNEqMpCxNmdC-12BHJiL2LibH8h_mqh5594dXPb0nwY2hH3JfY-zdKU7X0uHOxBfKKctNp41v0sSG9FR2AzY2I-A2E45uwo0ewrI3nc3dgi1X3YbdD32R_g586hiRWV2yz36a1gyndJ_VFdtfa35lp4s5yd417KJip22Dtj8pYFhZ5ucVOEZRzR8TNXfh7EoEew-2q7pyD4ChsFIYUxgneGqF0Mh15nI0WBai4DyAl0sBKtPTmvvpGhPVltdFptbkHcDz1fLLjs9j08IXrTZUPdMX6gdXnoe7vV5Mvio0SjtF0DVXshBpHMCAdKYq9226abvBmjpXL-cewCWSFuwt9av6MNKoldEHwFZPyf99UQcrVy9oCUFuzumrN4D7nVX83drTFRLee_jfrZ_ALnmSen90crwH17vmiCKM-CPYns8W7jFhrrketNbN4Pyq3ekPeN0_Qg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+sibutramine+on+cardiovascular+outcomes+in+overweight+and+obese+subjects&rft.jtitle=The+New+England+journal+of+medicine&rft.au=James%2C+W+Philip+T&rft.au=Caterson%2C+Ian+D&rft.au=Coutinho%2C+Walmir&rft.au=Finer%2C+Nick&rft.date=2010-09-02&rft.issn=1533-4406&rft.eissn=1533-4406&rft.volume=363&rft.issue=10&rft.spage=905&rft_id=info:doi/10.1056%2FNEJMoa1003114&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |